Other News To Note
Tuesday, June 19, 2012
Forma Therapeutics, of Watertown, Mass., and TGen Drug Development, of Scottsdale, Ariz., a subsidiary of the Phoenix-based Translational Genomics Research Institute, agreed to jointly develop transformative cancer therapies. Forma targets essential cancer pathways to create small-molecule cancer therapies. TGen will bring preclinical and clinical development capabilities to Forma.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.